Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease

Correlation with cognitive impairment

Steven T. DeKosky, Milos D. Ikonomovic, Xiaoyan Wang, Martin Farlow, Stephen Wisniewski, Oscar L. Lopez, James T. Becker, Judith Saxton, William E. Klunk, Robert Sweet, Daniel I. Kaufer, M. Ilyas Kamboh

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

α-1-Antichymotrypsin (ACT) is present in neuritic plaques in which it participates in the inflammatory cascade of Alzheimer's disease (AD). Reports of blood ACT levels in AD, and its usefulness as a disease biomarker, have been conflicting. In an effort to clarify this, we measured plasma ACT levels in 516 white subjects including 359 subjects with probable or possible AD, 44 subjects with other late-life dementias, and 113 nondemented people. Subjects with systemic inflammatory diseases or who were taking antiinflammatory medications were excluded. All patients underwent extensive medical and detailed neuropsychological examinations at the time their blood was drawn. We found that plasma ACT levels were elevated in AD patients compared with the control group (p = 0.01) and were associated with severity of AD dementia; there was a negative association with the Mattis Dementia Rating Scale (a global measure of cognition) and a positive association with the Clinical Dementia Rating Scale (a global functional assessment). These relationships remained significant after controlling for demographic and genetic variables. When AD subjects were stratified into sub-groups by dementia severity, matched by age, education, and gender, increased serum ACT correlated with Clinical Dementia Rating Scale (p = 0.0041) or Mattis Dementia Rating Scale (p = 0.0031) scores. ACT measurements in cerebrospinal fluid from an additional 34 AD cases and 16 controls showed elevated levels (p = 0.02) in AD. There was a negative correlation (p = 0.037) between cerebrospinal fluid ACT levels and clinical severity as measured by the Mini-Mental State Examination. Our results demonstrate that peripheral ACT levels are elevated in AD, but not in dementias other than AD, and they increase with progression of AD dementia. Although not useful as a diagnostic biomarker, ACT may reflect disease severity and may be helpful as a within subject biomarker in interventions (particularly with antiinflammatory agents) directed at slowing or halting progression of disease.

Original languageEnglish
Pages (from-to)81-90
Number of pages10
JournalAnnals of Neurology
Volume53
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Cerebrospinal Fluid
Alzheimer Disease
Dementia
Biomarkers
Cognitive Dysfunction
Anti-Inflammatory Agents
Amyloid Plaques
Cognition
Disease Progression
Demography
Education
Control Groups

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease : Correlation with cognitive impairment. / DeKosky, Steven T.; Ikonomovic, Milos D.; Wang, Xiaoyan; Farlow, Martin; Wisniewski, Stephen; Lopez, Oscar L.; Becker, James T.; Saxton, Judith; Klunk, William E.; Sweet, Robert; Kaufer, Daniel I.; Kamboh, M. Ilyas.

In: Annals of Neurology, Vol. 53, No. 1, 01.01.2003, p. 81-90.

Research output: Contribution to journalArticle

DeKosky, ST, Ikonomovic, MD, Wang, X, Farlow, M, Wisniewski, S, Lopez, OL, Becker, JT, Saxton, J, Klunk, WE, Sweet, R, Kaufer, DI & Kamboh, MI 2003, 'Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment', Annals of Neurology, vol. 53, no. 1, pp. 81-90. https://doi.org/10.1002/ana.10414
DeKosky, Steven T. ; Ikonomovic, Milos D. ; Wang, Xiaoyan ; Farlow, Martin ; Wisniewski, Stephen ; Lopez, Oscar L. ; Becker, James T. ; Saxton, Judith ; Klunk, William E. ; Sweet, Robert ; Kaufer, Daniel I. ; Kamboh, M. Ilyas. / Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease : Correlation with cognitive impairment. In: Annals of Neurology. 2003 ; Vol. 53, No. 1. pp. 81-90.
@article{28a0899f4488413e82292633f6594002,
title = "Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment",
abstract = "α-1-Antichymotrypsin (ACT) is present in neuritic plaques in which it participates in the inflammatory cascade of Alzheimer's disease (AD). Reports of blood ACT levels in AD, and its usefulness as a disease biomarker, have been conflicting. In an effort to clarify this, we measured plasma ACT levels in 516 white subjects including 359 subjects with probable or possible AD, 44 subjects with other late-life dementias, and 113 nondemented people. Subjects with systemic inflammatory diseases or who were taking antiinflammatory medications were excluded. All patients underwent extensive medical and detailed neuropsychological examinations at the time their blood was drawn. We found that plasma ACT levels were elevated in AD patients compared with the control group (p = 0.01) and were associated with severity of AD dementia; there was a negative association with the Mattis Dementia Rating Scale (a global measure of cognition) and a positive association with the Clinical Dementia Rating Scale (a global functional assessment). These relationships remained significant after controlling for demographic and genetic variables. When AD subjects were stratified into sub-groups by dementia severity, matched by age, education, and gender, increased serum ACT correlated with Clinical Dementia Rating Scale (p = 0.0041) or Mattis Dementia Rating Scale (p = 0.0031) scores. ACT measurements in cerebrospinal fluid from an additional 34 AD cases and 16 controls showed elevated levels (p = 0.02) in AD. There was a negative correlation (p = 0.037) between cerebrospinal fluid ACT levels and clinical severity as measured by the Mini-Mental State Examination. Our results demonstrate that peripheral ACT levels are elevated in AD, but not in dementias other than AD, and they increase with progression of AD dementia. Although not useful as a diagnostic biomarker, ACT may reflect disease severity and may be helpful as a within subject biomarker in interventions (particularly with antiinflammatory agents) directed at slowing or halting progression of disease.",
author = "DeKosky, {Steven T.} and Ikonomovic, {Milos D.} and Xiaoyan Wang and Martin Farlow and Stephen Wisniewski and Lopez, {Oscar L.} and Becker, {James T.} and Judith Saxton and Klunk, {William E.} and Robert Sweet and Kaufer, {Daniel I.} and Kamboh, {M. Ilyas}",
year = "2003",
month = "1",
day = "1",
doi = "10.1002/ana.10414",
language = "English",
volume = "53",
pages = "81--90",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease

T2 - Correlation with cognitive impairment

AU - DeKosky, Steven T.

AU - Ikonomovic, Milos D.

AU - Wang, Xiaoyan

AU - Farlow, Martin

AU - Wisniewski, Stephen

AU - Lopez, Oscar L.

AU - Becker, James T.

AU - Saxton, Judith

AU - Klunk, William E.

AU - Sweet, Robert

AU - Kaufer, Daniel I.

AU - Kamboh, M. Ilyas

PY - 2003/1/1

Y1 - 2003/1/1

N2 - α-1-Antichymotrypsin (ACT) is present in neuritic plaques in which it participates in the inflammatory cascade of Alzheimer's disease (AD). Reports of blood ACT levels in AD, and its usefulness as a disease biomarker, have been conflicting. In an effort to clarify this, we measured plasma ACT levels in 516 white subjects including 359 subjects with probable or possible AD, 44 subjects with other late-life dementias, and 113 nondemented people. Subjects with systemic inflammatory diseases or who were taking antiinflammatory medications were excluded. All patients underwent extensive medical and detailed neuropsychological examinations at the time their blood was drawn. We found that plasma ACT levels were elevated in AD patients compared with the control group (p = 0.01) and were associated with severity of AD dementia; there was a negative association with the Mattis Dementia Rating Scale (a global measure of cognition) and a positive association with the Clinical Dementia Rating Scale (a global functional assessment). These relationships remained significant after controlling for demographic and genetic variables. When AD subjects were stratified into sub-groups by dementia severity, matched by age, education, and gender, increased serum ACT correlated with Clinical Dementia Rating Scale (p = 0.0041) or Mattis Dementia Rating Scale (p = 0.0031) scores. ACT measurements in cerebrospinal fluid from an additional 34 AD cases and 16 controls showed elevated levels (p = 0.02) in AD. There was a negative correlation (p = 0.037) between cerebrospinal fluid ACT levels and clinical severity as measured by the Mini-Mental State Examination. Our results demonstrate that peripheral ACT levels are elevated in AD, but not in dementias other than AD, and they increase with progression of AD dementia. Although not useful as a diagnostic biomarker, ACT may reflect disease severity and may be helpful as a within subject biomarker in interventions (particularly with antiinflammatory agents) directed at slowing or halting progression of disease.

AB - α-1-Antichymotrypsin (ACT) is present in neuritic plaques in which it participates in the inflammatory cascade of Alzheimer's disease (AD). Reports of blood ACT levels in AD, and its usefulness as a disease biomarker, have been conflicting. In an effort to clarify this, we measured plasma ACT levels in 516 white subjects including 359 subjects with probable or possible AD, 44 subjects with other late-life dementias, and 113 nondemented people. Subjects with systemic inflammatory diseases or who were taking antiinflammatory medications were excluded. All patients underwent extensive medical and detailed neuropsychological examinations at the time their blood was drawn. We found that plasma ACT levels were elevated in AD patients compared with the control group (p = 0.01) and were associated with severity of AD dementia; there was a negative association with the Mattis Dementia Rating Scale (a global measure of cognition) and a positive association with the Clinical Dementia Rating Scale (a global functional assessment). These relationships remained significant after controlling for demographic and genetic variables. When AD subjects were stratified into sub-groups by dementia severity, matched by age, education, and gender, increased serum ACT correlated with Clinical Dementia Rating Scale (p = 0.0041) or Mattis Dementia Rating Scale (p = 0.0031) scores. ACT measurements in cerebrospinal fluid from an additional 34 AD cases and 16 controls showed elevated levels (p = 0.02) in AD. There was a negative correlation (p = 0.037) between cerebrospinal fluid ACT levels and clinical severity as measured by the Mini-Mental State Examination. Our results demonstrate that peripheral ACT levels are elevated in AD, but not in dementias other than AD, and they increase with progression of AD dementia. Although not useful as a diagnostic biomarker, ACT may reflect disease severity and may be helpful as a within subject biomarker in interventions (particularly with antiinflammatory agents) directed at slowing or halting progression of disease.

UR - http://www.scopus.com/inward/record.url?scp=0037231452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037231452&partnerID=8YFLogxK

U2 - 10.1002/ana.10414

DO - 10.1002/ana.10414

M3 - Article

VL - 53

SP - 81

EP - 90

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -